Prananda Arya Tjipta, Halim Princella, Syahputra Rony Abdi
Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
Department of Pharmacology, Faculty of Pharmacy, Universitas Sumatera Utara, Medan, Indonesia.
Front Pharmacol. 2025 Mar 6;16:1532986. doi: 10.3389/fphar.2025.1532986. eCollection 2025.
Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, with complex pathophysiological mechanisms such as oxidative stress, inflammation, apoptosis, and endothelial dysfunction driving disease progression. MicroRNAs (miRNAs), a class of non-coding RNAs, have emerged as key regulators of gene expression involved in these processes, positioning them as potential biomarkers and therapeutic targets in CVD management. Simultaneously, flavonoids, naturally occurring polyphenolic compounds found in various plant-based foods, have gained attention for their cardioprotective properties, including antioxidant, anti-inflammatory, and anti-apoptotic effects. Recent studies suggest a novel intersection between flavonoids and miRNAs, where flavonoids may modulate the expression of specific miRNAs implicated in CVD pathogenesis. This review explores the potential of flavonoids as miRNA modulators, focusing on their ability to regulate miRNAs associated with cardiac fibrosis, hypertrophy, and vascular inflammation. By bridging the therapeutic potential of flavonoids with miRNA targeting, this review highlights innovative pathways for advancing CVD treatment strategies. Additionally, preclinical and clinical evidence supporting these interactions is discussed, alongside the challenges and opportunities in developing flavonoid-based miRNA therapies. Unlocking this synergy could pave the way for more effective, personalized approaches to CVD management, addressing unmet needs in contemporary cardiovascular care.
心血管疾病（CVD）仍然是全球主要的死亡原因，氧化应激、炎症、细胞凋亡和内皮功能障碍等复杂的病理生理机制推动着疾病的进展。微小RNA（miRNA）是一类非编码RNA，已成为参与这些过程的基因表达的关键调节因子，使其成为心血管疾病管理中潜在的生物标志物和治疗靶点。同时，黄酮类化合物是在各种植物性食物中发现的天然多酚化合物，因其心脏保护特性，包括抗氧化、抗炎和抗凋亡作用而受到关注。最近的研究表明黄酮类化合物与微小RNA之间存在新的交叉点，其中黄酮类化合物可能调节与心血管疾病发病机制相关的特定微小RNA的表达。本综述探讨了黄酮类化合物作为微小RNA调节剂的潜力，重点关注其调节与心脏纤维化、肥大和血管炎症相关的微小RNA的能力。通过将黄酮类化合物的治疗潜力与微小RNA靶向相结合，本综述强调了推进心血管疾病治疗策略的创新途径。此外，还讨论了支持这些相互作用的临床前和临床证据，以及开发基于黄酮类化合物的微小RNA疗法所面临的挑战和机遇。解开这种协同作用可能为更有效、个性化的心血管疾病管理方法铺平道路，满足当代心血管护理中未满足的需求。
